GlassScriptPhysician profile
Anna Irwin
NPI 1407033228
$3,452.40
in general payments reported to CMS, 2019-2025
29 companies · $311 in 2025
The $311 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $791 · 2020: $335 · 2021: $182 · 2022: $1,650 · 2023: $135 · 2024: $48.47 · 2025: $311.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $494.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $494.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $1,650.00 | 2022 | |
| Supernus Pharmaceuticals, INC. | $286.63 | 2019-2020 | |
| Medtronic, INC. | $233.97 | 2023-2025 | Intellis Adaptivestim |
| Novartis Pharmaceuticals Corporation | $190.34 | 2019-2024 | |
| Abbott Laboratories | $184.11 | 2025 | Proclaim |
| Acadia Pharmaceuticals INC | $95.53 | 2019-2021 | |
| Emd Serono, INC. | $84.46 | 2019 | |
| Sk Life Science, INC. | $78.59 | 2020 | |
| Allergan, INC. | $68.22 | 2019-2021 | |
| Genzyme Corporation | $54.19 | 2019-2020 | |
| Lilly USA, LLC | $50.10 | 2019 | |
| Pfizer INC. | $50.01 | 2023-2024 | |
| Greenwich Biosciences, INC. | $46.30 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $43.86 | 2019-2021 | |
| Abbvie INC. | $43.63 | 2021 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $33.38 | 2021 | |
| Csl Behring | $32.29 | 2019-2020 | |
| Acorda Therapeutics, INC | $28.34 | 2020 | |
| Genentech USA, INC. | $28.26 | 2019-2020 | |
| Biogen, INC. | $27.29 | 2019 | |
| Lundbeck LLC | $20.17 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $20.16 | 2019 | |
| Alexion Pharmaceuticals, INC. | $18.05 | 2019 | |
| Saol Therapeutics INC. | $15.22 | 2019 | |
| Sunovion Pharmaceuticals INC. | $14.98 | 2019 | |
| Adamas Pharmaceuticals, INC. | $14.92 | 2019 | |
| Amneal Pharmaceuticals LLC | $14.60 | 2019 | |
| Neurelis, INC. | $13.61 | 2020 | |
| Merck Sharp & Dohme LLC | $11.19 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anna Irwin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.